1FOX RI, HERRMANN ML, FRANGOU CG, et al. Mechanism of action for leflunomide inrheumatoid arthritis[J]. Clin Immunol, 1999, 93(3):198-208.
2LAO ZY, NI LQ, ZHANG ZL, et al. Leflunomide in treating rheumato id arthritis: adouble-blind study[J]. Chin J New Drugs Clin Rem(in Chinese), 2001, 2(2):94-96.
4ROTMAN B. Clinical experience with leflunomide in rheumatoid arthrit is.Leflunomide investigators group[J]. J Rheumatal (Suppl), 1998, 53(1):27 -32.
5COHEN S, WEAVER A, SCHIFF M, et al. Two-year treatment of activ e rheumatoidarthritis(RA) with leflunomide (Lef) compare with placebo[J]. Ar thritis Rheum, 1999, 42(9Suppl): S271,abstract 1201.
6KALDEN J, SCHATTENKIRCH M, SMOLEN J, et al. Leflunomide vs sulfasalazine inrheumatoid arthritis: 24 months update of a randomized double b lind study[J]. ArthritisRheum, 1999, 42(9 Suppl):S271,abstract 1202.
7FOX RI. Mechanism of actionleflunomide in rheumatoid arthrit is[J]. J Rheumatol (Suppl), 1998, 53(1):20-26.
2Chi CM, King YY, Sydney T, et al. Predictor and outcome of renal flares after successful cyclophosphamide treatmem for diffuse proliferative lupus glomerulonephritis. Arthritis Rheumatism, 2004, 50(8): 2559-2568.
3Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus, 2008, 17(7): 638-644.
4Liu XW, Li DM, Xu GS, et al. Comparison of the therapeutic effects of leflunomide and myeophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. Int J Clin Pharmacol Ther,2010, 48(8): 509-513.
5Targo n ska-Stgpniak B, Dryglewska M, Majdan M. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients. Pharmacol Rep, 2010, 62(4): 719- 725.
6Ginzler EM, Dooley MA, Aranow C,et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Eng J Med, 2005,353(21 ) : 2219-2228.
